Literature DB >> 22114963

Simplifying the treatment of acute bacterial bone and joint infections in children.

Markus Pääkkönen1, Heikki Peltola.   

Abstract

The treatment of acute hematogenous bone and joint infections of children - osteomyelitis (OM), septic arthritis (SA) and OM-SA combination (OM+SA) - has simplified over the past years. The old approach included months-long antibiotic treatment, started intravenously for at least a week, followed by oral completion of the course. Recent prospective randomized trials show that most cases heal with a total course of 3 weeks (OM, OM+SA) or 2 weeks (SA) of an appropriate antibiotic, provided the clinical response is good and C-reactive protein level has normalized. If the prevalence of methicillin-resistant Staphylococcus aureus and Kingella kingae is low, clindamycin and a first-generation cephalosporin are safe, inexpensive and effective alternatives. They should be administered in large doses and four times a day. Clindamycin, vancomycin and expensive linezolid are options against methicillin-resistant Staphylococcus aureus. Extensive surgery beyond a diagnostic sample by aspiration is rarely needed in uncomplicated cases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22114963     DOI: 10.1586/eri.11.140

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  3 in total

Review 1.  Update on the Management of Pediatric Acute Osteomyelitis and Septic Arthritis.

Authors:  Luca Castellazzi; Marco Mantero; Susanna Esposito
Journal:  Int J Mol Sci       Date:  2016-06-01       Impact factor: 5.923

2.  Short therapy in a septic arthritis of the neonatal hip.

Authors:  Antonio Gatto; Ilaria Lazzareschi; Roberta Onesimo; Rossella Iannotta; Donato Rigante; Lavinia Capossela; Simona Filoni; Piero Valentini
Journal:  Pediatr Rep       Date:  2019-09-27

3.  Osteomyelitis of Maxilla in Infantile With Periorbital Cellulitis: A Case Report.

Authors:  Zhiqiang Feng; Xufeng Chen; Fengdi Cao; Renfa Lai; Qiang Lin
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.